RecruitingNCT05357612
Testing a serotonin 2A PET tracer in neurodegenerative diseases
About this title
Read the official source — NCT05357612Medication studyAges 50–85United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 50 years to 85 years.
- Listed locations
- NashvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 23, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 75
- Sponsor
- Vanderbilt University Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 50 Years to 85 Years
- Official registry ID
- NCT05357612
- Official title
Show the full official title
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Nashville
Questions about this study
Who is behind this study?
The study sponsor is Vanderbilt University Medical Center, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Pimavanserin.
Who can participate?
Listed age limits: 50 years to 85 years.
Is this study still recruiting?
The registry lists this study as recruiting.
